Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.75 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 11/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343716 | 0.86 | FGFR1 (1.00) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL122653 | 0.86 | FGFR1 (1.00) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL23675169 | 0.85 | FGFR1 (0.77) | FGFR1THRBHPGDALDH1A1 | |
| SCHEMBL2342155 | 0.85 | FGFR1 (0.77) | FGFR1THRBHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL121454 | 0.85 | FGFR1 (0.76) | FGFR1THRBHPGDALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7986291 | 0.85 | FGFR1 (0.97) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL2335780 | 0.84 | FGFR1 (0.75) | FGFR1THRBHPGDTP53SMN1; SMN2 | |
| SCHEMBL2649378 | 0.83 | FGFR1 (0.78) | FGFR1THRBHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL121462 | 0.83 | THRB (1.00) | FGFR1THRBHPGDMAPK1ALDH1A1 | |
| SCHEMBL28685131 | 0.82 | FGFR1 (0.85) | FGFR1THRBHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485658-B2 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485658-B2 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485658-B2 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1664032-B1 | N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARM INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| EP-1664032-A1 | N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060035951-A1 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | BOLGER JOSHUA | 2006-02-16 | — | — | US | disclosed |
| WO-2005021537-A1 | N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | KIT, TNNI3K, CHUK | FGFR1 994/4885THRB 3322/4885HPGD 756/4885 |
| US-20060035951-A1 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | KIT, TNNI3K, CHUK | FGFR1 994/4885THRB 3322/4885HPGD 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.